Histological grade, p53, HER2 and hormone receptor status of synchronous bilateral breast carcinoma

被引：22
作者：
Matsuo K. [1 ]
Fukutomi T. [1 ]
Akashi-Tanaka S. [1 ]
Hasegawa T. [2 ]
Tsuda H. [3 ]
机构：
[1] Department of Surgical Oncology, National Cancer Center Hospital, Chuo-ku, Tokyo 104-00459, 1-1
[2] Pathology Division, National Cancer Center Research Institute
[3] Pathdogy Division, National Defense Medical College
来源：
Breast Cancer | 2002年 / 9卷 / 2期
关键词：
Bilateral synchronous breast carcinoma; Estrogen receptor; HER2; p53; Progesterone receptor;
D O I：
10.1007/BF02967577
中图分类号：
学科分类号：
摘要：
Background and Objectives: Histological grade and tumor biology remain important predictors of the clinical behavior of breast carcinomas. We analyzed the clinicopathological characteristics and tumor biology with regard to histological grade (HG), p53, HER2 and hormone receptor status to address this question. Patients and Methods: A consecutive series of 74 female synchronous bilateral breast carcinoma patients treated at the National Cancer Center Hospital were the primary source of these retrospective data. Clinicopathological background factors, histological grade and immunohistochemical staining for p53, HER2 and hormone receptor status, were analyzed. Results: Of 148 synchronous bilateral tumors, 102 were invasive ductal carcinoma (IDC). The others included 24 pure or predominant ductal carcinoma in situ (DCIS), 5 spindle cell carcinomas, 16 invasive lobular carcinomas and 1 squamous cell carcinoma. 128 cases (128/148: 89%) were HG 1 (72/148: 49%) or HG 2 (56/148: 38%). The positivity rates for p53, HER2, estrogen receptor (ER) and progesterone receptor (PR) were 9% (14/148), 18% (26/148), 64% (95/148) and 64% (95/148), respectively. Conclusion: Our findings indicate that synchronous bilateral breast carcinomas showed a higher frequency of invasive lobular carcinoma, lower HG and higher rate of hormone receptor positivity than unilateral breast carcinomas.
引用
收藏
页码：127 / 133
页数：6
相关论文
共 28 条
  • [1] Adami H.O., Bergstrom R., Hansen J., Age at first primary as a determinant of the incidence of bilateral breast cancer Cumulative and relative risk in a population- based case-control study, Cancer, 55, pp. 643-648, (1985)
  • [2] Sardi A., Facundus E.C., Eckholdt G.J., Et al., Management of cancer to the opposite breast following breast preservation, Int Surg, 77, pp. 289-292, (1992)
  • [3] Stephan M., Irenans A.A., Christoph T., Et al., Bilateral breast carcinoma versus unilateral disease. Review of 498 patients, Am J Clin Onco, 120, pp. 541-545, (1997)
  • [4] Leis H.P., Management of the remaining breast, Cancer, 46, pp. 1026-1030, (1980)
  • [5] Solin L.J., Fowble B.L., Schultz D.J., Goodman R.L., Bilateral breas carcinoma treated with definitive irradiation, International Journal of Radiation Oncology Biology Physics, 17, 2, pp. 263-271, (1989)
  • [6] Fukutomi T., Counter Point, pp. 315-319, (1997)
  • [7] Tsuda H., Hirohashi S., Shimosato Y., Hirota T., Tsugane S., Watanabe S., Terada M., Yamamoto H., Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. A retrospective analysis of 176 cases, Cancer, 65, 8, pp. 1794-1800, (1990)
  • [8] Hjg B., Richardson W.W., Histological grading and prognosis in breast cancer, Br J Cancer, 11, pp. 359-377, (1957)
  • [9] Iwaya K., Tsuda H., Hiraide H., Et al., Nuclear p53 immunoreaction associated with poor prognosis of breast cancer, Jpn J Cancer Res, 82, pp. 835-840, (1991)
  • [10] Tsuda H., Iwaya K., Fukutomi T., Hirohashi S., P53 mutations and c-erbB-2 amplification in intraductal and invasive breast carcinomas of high histologic grade, Japanese Journal of Cancer Research, 84, 4, pp. 394-401, (1993)
123